Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Dasatinib and Imatinib-Induced Reductions in BCR-ABL Transcript Levels Below 10% At 3 Months Are Associated with Improved Responses in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Analysis of Molecular Response Kinetics in the DASISION Trial

Andreas Hochhaus, MD, Giuseppe Saglio, MD, Charles Chuah, MD, Carolina Pavlovsky, MD, M. Brigid Bradley Garelick, MD, Alexandre Lambert, Neil Shah, MD, PhD

Blood (2011) 118 (21): 2767.

https://doi.org/10.1182/blood.V118.21.2767.2767

Published: 2011

Journal Articles

Significance of ELN Provisional Response Definitions In Predicting Long-Term Outcomes of Patients with CP-CML Treated with Dasatinib After Imatinib Failure.

Jorge E. Cortes, MD, Neil P. Shah, Charles A. Schiffer, Philipp D. LeCoutre, Priv.-Doz., Dr., med., Giuseppe Saglio, MD, PhD, Alfonso Quintás-Cardama, MD, Hagop Kantarjian, MD, Elias Jabbour, MD, Erkut Bahceci, Allen Chen, Alexandre Lambert, Francois Guilhot

Blood (2010) 116 (21): 3439.

https://doi.org/10.1182/blood.V116.21.3439.3439

Published: 2010

Journal Articles

Patients with Chronic Myeloid Leukemia In Chronic Phase Carrying More Than One BCR-ABL Kinase Domain Mutation Exhibit Poorer Response Rates and Outcomes to Second-Line Dasatinib Compared to Those with No or Only One BCR-ABL Mutation

Alfonso Quintás-Cardama, Hagop Kantarjian, Neil P. Shah, Charles A. Schiffer, Philipp le Coutre, Giuseppe Saglio, Francois Guilhot, Andreas Hochhaus, Martin C. Müller, Erkut Bahceci, Alexandre Lambert, Jorge E. Cortes

Blood (2010) 116 (21): 2297.

https://doi.org/10.1182/blood.V116.21.2297.2297

Published: 2010

Journal Articles

Resistance, Outcome and the Development of Mutations with Dasatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP).

Neil Shah, Erkut Bahceci, Alexandre Lambert, Lynn Ploughman, Jerald Radich

Blood (2009) 114 (22): 1122.

https://doi.org/10.1182/blood.V114.22.1122.1122

Published: 2009

Journal Articles

Predictors of Long-Term Cytogenetic Response Following Dasatinib Therapy of Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP).

Elias Jabbour, Erkut Bahceci, Chao Zhu, Alexandre Lambert, Jorge Cortes

Blood (2009) 114 (22): 3296.

https://doi.org/10.1182/blood.V114.22.3296.3296

Published: 2009

Journal Articles

Dasatinib Dose-Optimization in Chronic Phase Chronic Myeloid Leukemia (CML-CP): Two-Year Data from CA180-034 Show Equivalent Long-Term Efficacy and Improved Safety with 100 Mg Once Daily Dose

Neil P. Shah, MD, PhD, Dong-Wook Kim, MD, PhD, Hagop M. Kantarjian, MD, Philippe Rousselot, MD, PhD, Pedro Dorlhiac-Llacer, Jorge Milone, MD, Martin C Müller, MD, Yousif Matloub, Alexandre Lambert, Andreas Hochhaus, MD

Blood (2008) 112 (11): 3225.

https://doi.org/10.1182/blood.V112.11.3225.3225

Published: 2008

NARROW

Dasatinib and Imatinib-Induced Reductions in BCR-ABL Transcript Levels Below 10% At 3 Months Are Associated with Improved Responses in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Analysis of Molecular Response Kinetics in the DASISION Trial

Significance of ELN Provisional Response Definitions In Predicting Long-Term Outcomes of Patients with CP-CML Treated with Dasatinib After Imatinib Failure.

Patients with Chronic Myeloid Leukemia In Chronic Phase Carrying More Than One BCR-ABL Kinase Domain Mutation Exhibit Poorer Response Rates and Outcomes to Second-Line Dasatinib Compared to Those with No or Only One BCR-ABL Mutation

Resistance, Outcome and the Development of Mutations with Dasatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP).

Predictors of Long-Term Cytogenetic Response Following Dasatinib Therapy of Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP).

Dasatinib Dose-Optimization in Chronic Phase Chronic Myeloid Leukemia (CML-CP): Two-Year Data from CA180-034 Show Equivalent Long-Term Efficacy and Improved Safety with 100 Mg Once Daily Dose

Email alerts

ASH Publications

American Society of Hematology

Dasatinib and Imatinib-Induced Reductions in BCR-ABL Transcript Levels Below 10% At 3 Months Are Associated with Improved Responses in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Analysis of Molecular Response Kinetics in the DASISION Trial

Significance of ELN Provisional Response Definitions In Predicting Long-Term Outcomes of Patients with CP-CML Treated with Dasatinib After Imatinib Failure.

Patients with Chronic Myeloid Leukemia In Chronic Phase Carrying More Than One BCR-ABL Kinase Domain Mutation Exhibit Poorer Response Rates and Outcomes to Second-Line Dasatinib Compared to Those with No or Only One BCR-ABL Mutation

Resistance, Outcome and the Development of Mutations with Dasatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP).

Predictors of Long-Term Cytogenetic Response Following Dasatinib Therapy of Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP).

Dasatinib Dose-Optimization in Chronic Phase Chronic Myeloid Leukemia (CML-CP): Two-Year Data from CA180-034 Show Equivalent Long-Term Efficacy and Improved Safety with 100 Mg Once Daily Dose

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only